We are in the midst of a paradigm shift in the field, and new diagnostics and treatments that yield clinically significant improvement for the heterogeneous set of disorders known as schizophrenia are being developed.
The need to stay up-to-date with the most current evidence-based information is becoming harder than ever. For this reason, the authors identify and evaluate published research that may have a direct bearing on clinical practice.
A paradigm-shifting finding holds the potential to alter how we perceive brain-immune interactions for disorders like schizophrenia and Alzheimer disease. It would enable a more mechanistic approach to the study of the neuroimmunology of these and other disorders.
We talk about mental disorders as brain disorders, but what does that really mean? How does it change the way we think about autism, schizophrenia, depression, bipolar, and other illnesses? The answer to these questions are still evolving. More in this video exclusive with NIMH Director Thomas Insel, MD.
The psychiatrist’s role is to act as a consultant to maximize the likelihood of a successful taper and discontinuation and to minimize collateral morbidities or withdrawal complications. This slideshow features common scenarios in which a planned discontinuation of psychotropic medications occurs.